Video Series

Panelists discuss how addressing social and structural barriers is essential to achieving equitable outcomes in schizophrenia care.

Updated iMMagine-1 data presented at ASH 2025 show that anito-cel delivers deep, durable responses in heavily pretreated multiple myeloma.

Andrew Yee, MD, introduces the discussion by reviewing treatment challenges, patient education, and decision-making in relapsed/refractory multiple myeloma.

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space.

Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options.

Sustained long-term safety data for tildrakizumab strengthens the positioning of IL-23 inhibitors as a preferred choice, especially for patients with comorbidities or a history of infection, and suggests their potential use in combination therapies for psoriatic arthritis.

Zachary Contreras of Sharp Health Plan highlighted strategies discussed at AMCP Nexus for improving timely access to Monoclonal Migraine Receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

Zachary Contreras highlighted strategies discussed at AMCP Nexus for improving timely access to monoclonal migraine receptor (MMR) therapy through updated coverage pathways, specialist input, and real-time benefit checks.

Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how relapse intensifies clinical and economic burdens, reinforcing the need for adherence and prevention-focused care.

Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH management.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how early and sustained intervention can reshape schizophrenia’s chronic course and improve long-term quality of life.

Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.

Andrew Zelenetz, MD, PhD, discusses the dual strategy of using the duration of benefit metric and re-biopsy to navigate complex sequencing decisions in targeted lymphoma therapy.

Nerandomilast's tolerability and dual antifibrotic/immunomodulatory mechanism directly address the critical non-adherence issue with current therapies, positioning it as a potential first-line treatment for IPF and PPF despite remaining questions about very long-term efficacy and the need for biomarkers.

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, showed sustained efficacy in the FIBRONEER trials for IPF and PPF, achieving FDA approval for IPF in October 2025.

Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.

The NCCN guidance transitioned from a specific focus on rituximab to a broad, future-proof policy covering all FDA-approved biosimilars, which simplifies treatment decisions and promotes patient access.

Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis.

FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling timely intervention with dextromethorphan-bupropion and reducing clinical and economic burden.

Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.

Zachary Contreras of Sharp Health Plan discusses how dextromethorphan-bupropion may improve agitation management in Alzheimer disease while reducing healthcare costs and supporting patient-centered care.

Panelists discuss how stigma and symptom overlap delay accurate schizophrenia diagnosis and how early intervention can transform outcomes.